Revolution Medicines Inc（RVMD）财务数据RVMDRevolution Medicines Inc

Evaluating the bottom line, Revolution Medicines, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -79.09%, provide a clear picture of how effectively RVMD converts its operational activities into shareholder value.

In the context of the broader market, RVMD competes directly with industry leaders such as ABVX and BHC. With a market capitalization of $40.67B, it holds a leading position in the sector. When comparing efficiency, RVMD's gross margin of N/A stands against ABVX's N/A and BHC's 65.04%. Such benchmarking helps identify whether Revolution Medicines, Inc. is trading at a premium or discount relative to its financial performance.

Revolution Medicines has shown significant growth with a year-to-date change of +125.21% and a one-year change of +229.49%. However, the company is currently reporting substantial net losses, with Q2 2026 projected at -$644 million.